Biocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and...

Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...

At a recent industry summit, executives from Eli Lilly and Novo Nordisk unveiled their game plan for tackling weight-loss medications in In...

Mounjaro has made a splash in Indian healthcare, emerging as the go-to solution for both diabetes management and weight loss. This remarkab...

Despite an uptick in profits, Dr Reddy's Laboratories experienced a decline in share value. Analysts continue to express optimism, keeping ...

Novo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...

Indian drug cos are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin...

Novo Nordisk, a Danish pharmaceutical company renowned for its diabetes medicines, is now positioning itself as the world's leading weight-...